136 related articles for article (PubMed ID: 31775455)
1. [The safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with inermediate or higer-risk myelodysplastic syndrome].
Ai H; Wei XD; Yin QS; Mi RH; Chen L; Wang Q; Song YP
Zhonghua Nei Ke Za Zhi; 2019 Dec; 58(12):908-910. PubMed ID: 31775455
[TBL] [Abstract][Full Text] [Related]
2. [The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
Ai H; Wei XD; Yin QS; Wang P; Mi RH; Yuan FF; Chen L; Song YP
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):606-609. PubMed ID: 28789495
[TBL] [Abstract][Full Text] [Related]
3. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
Huang L; Liu Z; Jiang H; Li L; Fu R
J Investig Med; 2019 Oct; 67(7):1067-1075. PubMed ID: 30898879
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
Zhang YP; Wu WZ; Cui GX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1341-4. PubMed ID: 25338585
[TBL] [Abstract][Full Text] [Related]
5. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
J Control Release; 2017 Dec; 268():92-101. PubMed ID: 29042320
[TBL] [Abstract][Full Text] [Related]
6. Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.
Ye L; Ren Y; Zhou X; Mei C; Xu W; Ma L; Luo Y; Hu C; Ye X; Wei J; Lou Y; Jin J; Tong H
Blood Cells Mol Dis; 2019 Jul; 77():88-94. PubMed ID: 31005752
[TBL] [Abstract][Full Text] [Related]
7. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
8. [Clinical Efficacy Comparison of Ultralow Dose of Decitabine and Cyclosporine on Low-risk and Intermediate-risk Type 1 of Myelodysplastic Syndrome].
Luo X; Wu H; Ding Y; Chen YH; Liang AB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):510-4. PubMed ID: 27151020
[TBL] [Abstract][Full Text] [Related]
9. [Retrospective efficacy analysis of decitabine bridging allogeneic hematopoietic stem cell transplantation on the treatment of myelodysplastic syndrome].
Zheng H; Wang J; Zhou J; Wang P; Fu C; Wu D; Sun A; Qiu H; Jin Z; Han Y; Tang X; Ma X
Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):121-4. PubMed ID: 25778887
[TBL] [Abstract][Full Text] [Related]
10. [Effects of Low-Dose Decitabine on Soluble CD44, GDF11 Levels and Hematopoietic Function in Elderly Patients with MDS].
Guo SQ; Shi R; Chen YY; Liu S; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):509-514. PubMed ID: 30998162
[TBL] [Abstract][Full Text] [Related]
11. [Clinical Efficacy and Prognostic Factors of Decitabine for Treatment of Myelodysplastic Syndrome].
Bao ZH; Zhao HG; Yu HE
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1702-1707. PubMed ID: 30501707
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
Xiu C; Li X; Wu L; Xu F; He Q; Zhang Z; Wu D; Song L; Su J; Zhou L; Zhao Y; Tao Y; Chang C
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3089-3097. PubMed ID: 31559495
[TBL] [Abstract][Full Text] [Related]
15. The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years' experience of a single center.
Gao J; Hu Y; Gao L; Xiao P; Lu J; Hu S
BMC Pediatr; 2022 May; 22(1):312. PubMed ID: 35624441
[TBL] [Abstract][Full Text] [Related]
16. Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases.
Zhang K; Lian Y; Guan X; Hu Q; Lei L; Tao L; He D; Lin J; Hou Z; Ren L; Liu X; Ren Q; Pan L; Fei X; Xiong M; Wen S; Cao J
Ann Hematol; 2020 Nov; 99(11):2539-2546. PubMed ID: 32939674
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of Decitabine Rigimen and Traditional Chemotherapy Regimen in Treatment of Patients with Intermediate or High-Risk Myelodysplastic Syndrome].
Zhang QP; Han YS; Wan X; Sun GY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):197-201. PubMed ID: 29397843
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Efficacy of Low-Dose Decitabine alone for Treatment of Myelodysplastic Syndrome].
Shi R; Guo SQ; Chen YY; Liu S; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1568-1573. PubMed ID: 31607313
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia.
Tang Y; Zhang X; Han S; Chu T; Qi J; Wang H; Tang X; Qiu H; Fu C; Ruan C; Wu D; Han Y
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):217S-222S. PubMed ID: 30296835
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen].
Xu ZF; Qin TJ; Zhang HL; Fang LW; Zhang Y; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):572-577. PubMed ID: 28810323
[No Abstract] [Full Text] [Related]
[Next] [New Search]